Melissa Johnson was named program director of lung cancer research at Sarah Cannon.
In this role, Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.
Since joining Sarah Cannon in 2014, Johnson has served as the associate director of lung cancer research at Sarah Cannon Research Institute, supporting the growth of early phase compounds in thoracic malignancies.
Johnson will continue to work in early phase drug development as well as lead the Solid Tumor Immune Effector Cellular Therapy Program at Sarah Cannon. She is also the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville.
Johnson begins her position in January at Sarah Cannon headquarters in Nashville. She will continue to care for patients as a partner with Tennessee Oncology, PLLC.
